Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

• Main Authors: Morikawa K (Author), Nakamura A (Author), Shimazaki T (Author), Sakamoto N (Author)
• Format: Book
• Published: Dove Medical Press, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Kenichi Morikawa, Akihisa Nakamura, Tomoe Shimazaki, Naoya Sakamoto Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan Abstract: Treatments for hepatitis C virus (HCV) have advanced greatly, becoming more efficacious with fewer adverse events, due to the availability of direct-acting antiviral agents, which target specific steps in the HCV life cycle. Recently, a combination regimen consisting of the HCV nonstructural protein 5A inhibitor elbasvir (EBR) and the HCV NS3/4A protease inhibitor grazoprevir (GZR) was approved for the treatment of patients with chronic HCV and genotypes (Gts) 1 and 4 in various countries. In Phase III trials, the combination of EBR/GZR (fixed-dose combination table or single agent) for 12 or 16 weeks of treatment with or without ribavirin resulted in a high sustained virological response at 12 weeks in treatment-naïve and treatment-experienced patients with HCV Gt 1a, 1b, 4, or 6, including special populations, such as individuals with advanced chronic kidney disease, HCV-HIV coinfection, and compensated cirrhosis. In this review, we focus on the mode of action, pharmacokinetics, clinical applications, efficacy, and safety profile of EBR/GZR, including special populations who have been considered refractory from the extensive evidence of clinical trials. Keywords: HCV, DAAs, compensated LC, HCV/HIV

Item Description

1177-8881